Breast cancer metastatic+1
Not recruitingStudy of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment
Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment
- Disease:Breast cancer metastaticHER2 positive breast cancer
- Substances:Trastuzumab Deruxtecan
Spain- Participants:18–64 years · 65+ years
- Substances:Trastuzumab Deruxtecan










